Optimized Early-Phase Trials with Precision, Safety and Data-Driven Excellence
Accelsiors Phase I Unit specializes in the early-phase clinical trials, where we specifically focus on dose-escalation studies, such as Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies. Our methodologies combine proprietary techniques, excellent and advanced safety monitoring, as well as expert analysis to ensure optimized dosing decisions. To help align with your therapeutic goal, here at Accelsiors, we work closely in a collaborative way to ensure we create a tailored study protocol. Furthermore, by utilizing data-driven approaches, namely Quality-by-Design (QbD), real-world data integration and biomarker analysis, Accelsiors ensures safe outcomes both statistically and operationally.
Accelsiors Phase I Unit's Commitment to Innovation
Our Accelsiors Phase I Unit’s experience expands to First-in-Human (FIH), as well as early-phase trials, guaranteeing precision, safety, as well as efficiency throughout the transition from preclinical to clinical development, and beyond. Both volunteer and patient recruitment is brought through and ensured by a specialized database, alongside our strategic location within university hospital grounds, enabling collaborations with Site Management Organizations (SMOs).
Pharmacokinetic (PK) and pharmacodynamic (PD) modelling allows us here at Accelsiors to carefully analyze drug behavior. Meanwhile, our biomarker analysis supports therapeutic assessments as well as safety monitoring. Detailed safety protocols, including but not limited to adverse event reporting, risk mitigation, guarantee participants’ well-being, and exquisite clinical data. The Accelsiors dedication to innovation, along regulatory compliance, and our patient-centric mentality puts us at the forefront as a reliable partner for early-phase clinical trials.
Whether you have questions, or want to explore partnership opportunities, get in touch!
